Keywords: Bristol-Myers Squibb, Ipilimumab, Yervoy, Metastatic melanoma, Ph III, USA, Regulatory decision
Bristol-Myers Squibb’s ipilimumab achieves Ph III endpoints in metastatic melanoma
Article | 23 March 2011
US drug major Bristol-Myers Squibb (NYSE: BMY), which is awaiting a decision from the Food and Drug Administration on March 26 ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
